Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Xgeva® (denosumab) – Expanded indication
January 5, 2018 - Amgen announced the FDA approval of Xgeva (denosumab) for the prevention of skeletal-related events (SRE) in patients with multiple myeloma (MM).
